RETAIN-2: Risk-Enabled Therapy After Neoadjuvant Chemo-Immunotherapy for MIBC

2 Views
Published
At the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium, Pooja Ghatalia, MD, of Fox Chase Cancer Center, and Amanda Nizam, MD, of Cleveland Clinic, break down in detail the RETAIN-2 study, a phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer.
Category
Oncology
Be the first to comment